Pharmacokinetics of roflumilast and its active metabolite roflumilast N-oxide are not influenced by erythromycin Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Effect of CYP3A4 inhibitors verapamil and itraconazole on the pharmacokinetics of AZD7986, an oral DPP1 inhibitor Source: International Congress 2017 – Asthma management Year: 2017
Inhibition of human lung fibroblast functions by roflumilast N-oxide Source: Eur Respir J 2006; 28: Suppl. 50, 662s Year: 2006
Roflumilast and its active metabolite roflumilast N-oxide do not interact with R- and S-warfarin Source: Eur Respir J 2003; 22: Suppl. 45, 103s Year: 2003
Effect of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide Source: Eur Respir J 2006; 28: Suppl. 50, 435s Year: 2006
Roflumilast N-oxide reduces human fibroblast function Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007
Effects of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide Source: Annual Congress 2009 - New bronchodilators Year: 2009
The PDE4 inhibitor roflumilast N-oxide partly reversed TGFß1-induced changes in collagen I and E-cadherin expression in human airway epithelial cells Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
Roflumilast N-oxide, a selective PDE4 inhibitor, curbs platelet-leukocyte interactions Source: Annual Congress 2011 - Translational models of disease Year: 2011
Smoking has no effect on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Selective inhibition of COX-2 by celecoxib exerts negative effects on endothelial progenitor cell proliferation and stimulates apoptosis in vitro Source: Eur Respir J 2005; 26: Suppl. 49, 368s Year: 2005
Effects of steady-state female hormones on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
IL-8 and COX-2 expression is regulated through cPLA2-derived arachidonate metabolites in human lung cells Source: Annual Congress 2003 - Intracellular signalling and regulation of cytokine production Year: 2003
The effect of metabolite 1 of erdosteine on the elatase release from human neutrophils Source: Eur Respir J 2005; 26: Suppl. 49, 100s Year: 2005
Inhibition of heme oxygenase-1 enhances chemosensitivity of cisplatin in lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 336s Year: 2006
In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilastSource: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
High oral absolute bioavailability of roflumilast, a new, orally active, once daily PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 20s Year: 2001
Roflumilast N-oxide, a PDE4 inhibitor, curbs bleomycin-induced lung fibroblast activation in vitro Source: Annual Congress 2011 - Airway smooth muscle cells and fibroblasts: cell biology Year: 2011
Inhibition of VEGF and MMP-9 production by Pregabalin in human immunocompetent cells in vitro Source: Virtual Congress 2020 – New insight into the pathogenesis of chronic lung diseases: asthma, COPD and others Year: 2020